Articles from HCW Biologics, Inc

Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting

Showed HCW9218 clinical safety and tumor response endpointsfor 15 patients with heavily pretreated advanced solid tumors

By HCW Biologics, Inc · Via GlobeNewswire · November 8, 2023

Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting

HCW9218 is the lead product candidate of HCW Biologics Inc.

By HCW Biologics, Inc · Via GlobeNewswire · November 1, 2023

HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023

Company will provide an update for clinical development and intellectual property programs, Including recent achievements and expected milestones in the next 12 months

By HCW Biologics, Inc · Via GlobeNewswire · September 6, 2023

HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan

Provides funding for buildout of new headquarters and manufacturing facility

By HCW Biologics, Inc · Via GlobeNewswire · April 27, 2023

HCW Biologics Enters CRADA with National Cancer Institute

NCI Activated as Clinical Site for Phase 1b/2 Clinical Trial to Evaluate HCW9218 in Advanced Pancreatic Cancer

By HCW Biologics, Inc · Via GlobeNewswire · December 8, 2022